The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC).
 
Matthew Raymond Smith
No Relationships to Disclose
 
Chris Parker
Consulting or Advisory Role - Bayer Schering Pharma; BN ImmunoTherapeutics; Janssen
Research Funding - Bayer Schering Pharma (Inst)
Travel, Accommodations, Expenses - Bayer Schering Pharma; Janssen
 
Bertrand F. TOMBAL
Honoraria - Bayer; Janssen
Consulting or Advisory Role - Bayer; Janssen-Ortho
Speakers' Bureau - Bayer; Janssen
 
Kurt Miller
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Merck; Novartis
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Merck; Novartis
Speakers' Bureau - Janssen
 
Fred Saad
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Novartis; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bavarian Nordic; Janssen Oncology; Millennium; Novartis; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Oncogenex (Inst); Sanofi (Inst)
 
Fang Fang
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Amily Zhang
Employment - Bayer
 
Martin Kornacker
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Celestia S. Higano
Employment - Cell Therapeutics (I)
Leadership - Cell Therapeutics (I)
Stock and Other Ownership Interests - Cell Therapeutics (I)
Consulting or Advisory Role - AbbVie; Bayer; BHR Pharma; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Orion; Pfizer; Sanofi
Research Funding - Algeta/Bayer (Inst); Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Exelixis (Inst); Genentech (Inst); Medivation (Inst); Millennium (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AbbVie; Amgen; Astellas Pharma; Bayer; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Ockham; Orion; Pfizer; Sanofi; Teva